Antisynthetase syndrome is an autoimmune condition, characterized by antibodies directed against an aminoacycl transfer RNA synthetase along with clinical features that can include interstitial lung disease (ILD), myositis, Raynaud's phenomenon, and arthritis. There is a higher prevalence and increased severity of ILD in patients with antisynthetase syndrome, as compared with dermatomyositis and polymyositis, inflammatory myopathies with which it may overlap phenotypically. The diagnosis is made by a multidisciplinary approach, synthesizing rheumatology and pulmonary evaluations, along with serologic, radiographic, and occasionally muscle and/or lung biopsy results. Patients with antisynthetase syndrome often require multimodality immunosuppressive therapy to control the muscle and/or pulmonary manifestations of their disease. The long-term care of these patients mandates careful attention to the adverse effects and complications of chronic immunosuppressive therapy, and disease-related sequelae that can include progressive ILD necessitating lung transplantation, pulmonary hypertension, malignancy, and a decreased survival. It is expected that a greater awareness of the clinical features of this syndrome will allow for an earlier diagnosis and appropriate treatment to improve outcomes in patients with antisynthetase syndrome.
A ntisynthetase syndrome is an autoimmune disease characterized by autoantibodies against one of many aminoacyl transfer RNA (tRNA) synthetases with clinical features that may include interstitial lung disease (ILD), nonerosive arthritis, myositis, Raynaud's phenomenon, unexplained fever, and/or mechanic's hands. 1 Antisynthetase syndrome is an idiopathic inflammatory myopathy (IIM), with a higher prevalence of ILD compared with dermatomyositis (DM) and polymyositis (PM), IIMs with which it shares many features. The ILD in antisynthetase syndrome patients is often severe and rapidly progressive, causing much of the increased morbidity and mortality associated with antisynthetase syndrome as compared with other IIMs. 2 Since Bohan and Peter's 1975 classification of DM and PM, additional research has added to our understanding of the heterogeneous phenotypes of patients with IIMs. 3, 4 In the 1980s, aminoacyl tRNA synthetase autoantibodies were identified and linked to IIMs. 5, 6 In the early 1990s, several groups recognized that patients with these antibodies had distinct clinical features, leading to the formal recognition of antisynthetase syndrome. 7, 8 In addition, more subtle forms have been identified, including lung-dominant disease. Patients with antisynthetase syndrome have a higher incidence of pulmonary involvement and symptoms considered to be more characteristic of other connective tissue diseases (CTDs), such as Raynaud's phenomenon or gastroesophageal reflux. Patients with antisynthetase syndrome may have corticosteroidresistant myositis or ILD, frequently requiring additional immunosuppressive medications.
Evidence guiding the management of antisynthetase syndrome is primarily based on case series and reports. Historically, antisynthetase syndrome was not considered as a separate entity, and these patients were diagnosed with either DM or PM depending on their clinical presentation. Therefore, management decisions in antisynthetase syndrome are frequently extrapolated from studies on patients with IIM, which also includes patients with antisynthetase syndrome. Given the lack of prospective data to guide treatment decisions, management choices are typically made on the basis of practitioner experience and patient response to therapy.
This review summarizes the clinical, serologic, and radiographic features of antisynthetase syndrome, with particular attention to antisynthetase syndrome-associated ILD. We also review the existing evidence guiding the use of immunosuppressive therapy and the long-term clinical management of antisynthetase syndrome.
DIAGNOSIS Clinical Features
Peter and Bohan's 1975 criteria for diagnosing DM and PM served for decades as the framework for the classification of IIMs. 3, 4 Patients were grouped into 1 of 5 classification categories using muscle biopsy, electromyography, and serologic data along with physical examination findings. Since then, Dalakas and Holhfeld proposed revised diagnostic criteria in 2003, with a greater emphasis on histologic and immunologic pathology to distinguish between the IIM subtypes. 9 Although Dalakas and Holhfeld's revised criteria provided clarity for distinguishing between the IIMs, it was not until 2010 that formal criteria for the diagnosis of antisynthetase syndrome were introduced by Connors et al. 1 These criteria proposed that all patients with antisynthetase syndrome must have evidence for a tRNA synthetase autoantibody, in addition to one or more of the following clinical features: mechanic's hands, Raynaud's phenomenon, myositis, ILD, arthritis, and/or unexplained fever (Table 1 ). In 2011, Solomon and colleagues proposed alternative, stricter criteria, requiring 2 major or 1 major and 2 minor criteria, in addition to the presence of an aminoacyl tRNA synthetase autoantibody. 10 Historically, patients with these antibodies were diagnosed with an IIM or were unrecognized given their atypical clinical features. In fact, in a recent retrospective analysis of 198 patients with idiopathic interstitial pneumonia, 13 patients were later noted to have an antisynthetase antibody. 11 The diagnostic criteria proposed by Connors and colleagues and Solomon and colleagues permit the recognition of the antisynthetase syndrome as a distinct entity, which may be useful in both clinical and research settings. However, we caution that the absence of an antisynthetase antibody does not preclude the presence of the antisynthetase syndrome because autoantibody levels fluctuate depending on disease activity, 12 centers and laboratories vary in which autoantibodies they test routinely, and there may be undiscovered autoantibodies not yet available for laboratory detection. In our experience, we have encountered patients with clinical features of the antisynthetase syndrome phenotype along with rapidly progressive and severe ILD, who do not have evidence of antisynthetase antibodies. Although a formal diagnosis of antisynthetase syndrome is not possible if an antisynthetase antibody is not present, these patients may benefit from pharmacologic therapy as is recommended for patients formally diagnosed with antisynthetase syndrome.
Phenotypically, patients with antisynthetase syndrome often have signs and symptoms that overlap with other CTDs, such as Raynaud's phenomenon, severe gastroesophageal reflux disease, and nonerosive arthritis. ILD frequently predominates at presentation and contributes to the high morbidity and mortality in patients with antisynthetase syndrome. The prevalence of ILD in antisynthetase syndrome varies widely and is difficult to determine as these patients have only recently been studied as a distinct entity from other IIMs. In a 2013 study of 203 antisynthetase syndrome patients, the prevalence of ILD was 86%, more common than the prevalence of myositis (73%) or arthralgia/arthritis (60%). 13 In fact, antisynthetase syndrome patients may not have classic myopathic symptoms that are disease-defining in PM, 14 or the myositis may present later in the disease course. We examine the hands in patients with ILD carefully as the hyperkeratosis and scaling characteristic of mechanic's hands are often subtle findings, the presence of which should prompt further testing for antisynthetase antibodies and elevated muscle enzymes.
Depending on the clinical presentation, additional laboratory testing may help guide the clinical evaluation of the disease extent and organ involvement. 15 Myositis activity is typically assessed through elevations in creatinine kinase (CK) and aldolase. Monitoring these muscle enzymes in clinically amyopathic patients may uncover subclinical myositis, and can help track the muscle disease activity.
Autoantibodies
In patients with IIM, a variety of myositis-specific and associated autoantibodies have been described and are frequently tested in the evaluation of idiopathic ILD 16 ( Tables 2, 3 ). The hallmark of antisynthetase syndrome is the presence of myositis-specific antisynthetase antibodies ( Table 2 ). Of the antisynthetase antibodies, anti-Jo-1, an antihistidyl-tRNA synthetase, is the most commonly identified. Less common antisynthetase antibodies include antithreonyl (anti-PL7), antialanyl (anti-PL12), anti-isoleucyl (anti-OJ), and antigylcyl (anti-EJ), along with others tested infrequently in the clinical setting, but reported in the literature.
The diagnostic testing for idiopathic ILD also involves other myositis-specific autoantibodies ( Table 3) , including those against translational transport (antisignal recognition particle autoantibodies), RNA helicase (anti-MDA5 autoantibodies), 17 and nuclear helicase (anti-Mi-2 autoantibodies). 15 Myositis-associated autoantibodies often evaluated include, but are not limited to, antinuclear antibody, anti-Ro/SSA, 18 anti-PM-Scl, anti-Ku, and anti-U1-RNP 15 (Table 3) . Although anti-Ro/SSA and anti-La/SSB are traditionally associated with Sjogren's disease and Sjogren's-related ILD, anti-Ro/SSA has been independently associated with antisynthetase syndrome and more severe and fibrotic ILD by high-resolution computed tomography (HRCT). 18, 19 The reported prevalence of autoantibodies in patients with an IIM varies widely. In a 2006 study of 74 patients with IIM, 58% were positive for a myositis-specific autoantibody and 36% had a myositis-associated antibody (with overlap in 20% of the patients). 20 In this case series and others, anti-Jo-1 predominated, and was found to be prevalent in 30% of the cases (over half of all patients with myositis-specific antibodies were Jo-1 positive). A 2010 Australian study of patients with antisynthetase antibodies demonstrated a prevalence of the Jo- 
Anti-ARS Antibodies Autoantigen Clinical Features
Anti-Jo1* Histidyl Most common Anti-PL7* Theronyl Severe ILD Anti-PL12* Alanyl Severe ILD Anti-OJ* Isoleucyl Anti-EJ* Glycyl Anti-KS Asparaginyl Anti-Zo Phenylalanyl Anti-SC Lysyl Anti-JS Glutaminyl Anti-YRS Tyrosyl 1 antibody in 88% of the included patients. 21 In this study, female patients were more common than male patients (30:12) . The immunologic pathogenesis of these autoantibodies has not been precisely determined. Aminoacyl tRNA synthetases translate proteins from genetically transcribed mRNA. In 1999, Wakasugi and Schimmel 22 identified that these synthetases may act as cytokines, assisting in cell death and recruitment of inflammatory cells. Further studies, summarized by Ascherman in 2015, have identified innate and adaptive immunity in the pathogenesis of antisynthetase syndrome. 23 The clinical presentation and disease course differs depending on the antisynthetase antibody present. Hamaguchi et al 24 reviewed 166 patients with antisynthetase antibodies, and demonstrated that patients with anti-Jo-1, anti-EJ, and anti-PL-7 were most often clinically diagnosed with DM or PM, whereas patients with anti-PL-12 were most often clinically diagnosed with amyopathic DM or ILD alone. ILD alone was common in patients with anti-KS and anti-OJ. A 2012 study of the long-term outcomes of patients with an anti-Jo-1 autoantibody (n = 75) and anti-PL7/PL12 autoantibody (n = 20)
found that the prevalence of muscle symptoms (weakness and myalgia) was significantly lower in patients with anti-PL7/ PL12 as compared with those with anti-Jo1. 25 We recommend a high index of suspicion for antisynthetase syndrome particularly in patients with idiopathic ILD and/or acute respiratory distress syndrome (ARDS) of unknown etiology. Antisynthetase syndrome can present with fever, arthritis, or ILD in isolation. Therefore, we encourage physicians to consider this diagnosis in patients with unexplained acute or chronic interstitial pneumonia, and recommend a laboratory evaluation for antisynthetase antibodies in patients with otherwise unexplained ILD or acute lung injury.
Radiographic and Histopathologic Features of Antisynthetase Syndrome
HRCT imaging is routine in the workup and management of ILD (Figs. 1, 2). A 2015 study of the initial and follow-up CT images in 26 patients with antisynthetase syndrome found that traction bronchiectasis, ground-glass opacities, and reticulation are the most common radiographic features at initial diagnosis. 26 CT patterns most often identified were nonspecific interstitial pneumonia (NSIP), organizing pneumonia, or a combination of the 2. At a median follow-up of 27 months, 38% of the patients had evidence of honeycombing. The presence of NSIP and organizing pneumonia suggests an underlying autoimmune etiology and in our experience, is not uncommon in antisynthetase syndrome. 27 HRCT is used to monitor the disease activity, along with the history, a physical examination, and serologic testing.
Lung biopsy, including transbronchial biopsy, videoassisted thorascopic surgical biopsy, and surgical open-lung biopsy, is infrequently performed in patients with antisynthetase syndrome as the diagnosis is typically made by synthesizing HRCT findings, serologic data, pulmonary function testing, physical examination, and patient symptoms. Studies by Yousem and colleagues examined the histopathologic findings of patients, using open surgical lung biopsies, autopsies, and/or native lungs removed for transplantation, with anti-Jo-1 and anti-PL7 antibodies. In 20 patients with the anti-Jo-1 antibody, 50% had diffuse alveolar damage and 35% usual interstitial pneumonia on a surgical lung biopsy. 28 In 8 patients with anti-PL7, the lung biopsy showed usual interstitial pneumonia in half of the patients. 29 A 2008 study of transbronchial biopsy findings in patients with DM/PM and Tacrolimus was also initiated. The cyclophosphamide was subsequently switched to azathioprine after discharge from the hospital. Lung function normalized despite tapering off prednisone. Lung disease relapsed when patient self-discontinued tacrolimus. She is now back in remission on a prednisone taper, azathioprine, and tacrolimus.
interstitial pneumonia found that patients with bud-type fibrosis demonstrated an increased response to immunosuppressive therapy as well as survival, as compared with patients with mural incorporation-type fibrosis. 30 These studies, taken together, suggest that in antisynthetase syndrome, ILD may be severe, fibrotic, and/or refractory to therapy.
Myositis is often absent or subclinical in antisynthetase syndrome, with ILD being the primary clinical manifestation; therefore, muscle biopsy is not typically performed. Although a muscle biopsy is useful in the diagnosis of other IIMs, 31 there is no evidence regarding the role of muscle biopsy in the diagnosis of antisynthetase syndrome.
TREATMENT
Immunosuppressive agents treat the pulmonary and/or muscle manifestations of antisynthetase syndrome. Muscle and lung disease may not track together and require separate monitoring by collaborating rheumatologists and pulmonologists. Corticosteroids have long been the first line in the treatment of IIMs, although when corticosteroids are used as a monotherapy in antisynthetase syndrome, there is frequent lung disease recurrence with corticosteroid tapering. Additional immunosuppressive agents are added for refractory muscle and/or lung disease and as corticosteroid-sparing agents. Frequently used adjunctive agents include azathioprine, mycophenolate mofetil, tacrolimus, rituximab, and cyclophosphamide, although there is little consensus about which agent is preferred, and the use of these agents to treat antisynthetase syndrome-related ILD is off-label (Table 4) . When muscle and/or lung disease symptoms stabilize, providers typically taper corticosteroids slowly, to spare patients the long-term side effects. There is no evidence to guide providers about the length of immunosuppressive therapy, the rate of medication tapering, or the consequences of withdrawal even after a patient has entered a clinical remission. In the experience of this review's rheumatologist (J.J.C.), CK may never normalize completely in some African American patients. This is in line with previously published data that African American patients often have higher mean CK levels. 32 Careful laboratory and clinical evaluation is imperative for patients treated with immunosuppressive agents. Prescribing providers should be familiar with evidence-based immunosuppressive clinical guidelines. 33, 34 The aforementioned medications suppress the normal immune function in an effort to combat aberrant pathogenic autoimmunity. An unintended consequence for patients treated with all of these immunosuppressive agents is the increased risk of opportunistic infections and malignancy, particularly skin cancer and lymphoma. If patients are to be treated with corticosteroids and an additional immunosuppressive agent, we recommend Pneumocystis jiroveci prophylaxis. 35 Adherence to evidence-based vaccination recommendations is also necessary, although many immunosuppressive agents preclude the administration of live vaccinations. In addition, hepatitis B reactivation is common (up to 40%) in patients who are hepatitis B surface antigen positive and are treated with immunosuppressive agents. 36 Hepatitis B surface antigen, antihepatitis B core antigen, and hepatitis C antibody should be performed before the administration of prednisone or other immunosuppressive therapy. Guidelines recommend prophylactic antiviral therapy in patients at risk for hepatitis B reactivation. Patients with positive hepatitis serologies should be treated in consultation with a liver specialist.
We recommend a multidisciplinary approach to care for these patients, with close collaboration between rheumatologists and pulmonologists. Careful titration of the chosen agents, while monitoring the disease status and organ function, allows the safe administration of these medications, by practitioners experienced with their use. As noted previously, most data supporting the use of the following agents in antisynthetase syndrome are extrapolated from studies on DM and PM.
Corticosteroids
Since the first administration of "Compound E" in 1948, which would later be renamed "cortisone," to treat rheumatoid arthritis, corticosteroids have become nearly ubiquitous in the management of autoimmune conditions. 37 Corticosteroids have wide-ranging mechanisms of action in their role as analogs of adrenal cortex innate functions. In this context, corticosteroids are prescribed for their anti-inflammatory, immunosuppressive, and antiproliferative effects. They are the initial therapy given to treat active muscle and/or lung disease in patients with an IIM, with or without lung involvement. 38 Controlled trials have not been performed to establish the superiority of corticosteroids in the initial management of active disease, as compared with other immunosuppressive agents. A 1993 study of 113 patients with an IIM compared the efficacy of prednisone, methotrexate, and azathioprine by clinical and autoantibody groups. 38 The clinical response was mostly judged by myositis symptoms, and not by lung disease symptoms. The first trial of prednisone alone for 4 weeks resulted in a partial improvement in most patients with antisynthetase antibodies, but a complete clinical response was rare. Given these findings, patients with antisynthetase syndrome may require multimodality therapy at the outset, with frequent monitoring of lung function.
Adverse events in patients treated with corticosteroids in the long term are frequent, and include hyperglycemia, hypertension, weight gain, adrenal suppression, osteoporosis, and fractures, among many others. 39 Patients should be monitored closely, and corticosteroids should be tapered when clinically indicated.
Azathioprine
Azathioprine decreases the immune function by halting purine synthesis and incorporating metabolites into the DNA, thus stopping replication, particularly of immune cells. Azathioprine is frequently used as adjunctive therapy in patients with IIM-ILD, particularly in patients with corticosteroidresistant disease. Although there is little evidence demonstrating azathioprine's superiority as the preferred corticosteroidsparing immunosuppressive agent, azathioprine has been most frequently used as maintenance therapy often in conjunction with prednisone. 40 Evidence to support azathioprine's efficacy in the treatment of antisynthetase syndrome-ILD is largely driven by studies in patients with IIM with myositis-predominant symptoms. In 1980, a prospective, randomized controlled trial studied the use of azathioprine in PM in 16 patients, treated either with prednisone plus placebo or prednisone plus azathioprine. 41 This study demonstrated no significant difference in the muscle strength or the CK level after 3 months. A follow-up study in the same group of patients demonstrated that at 1 year, the prednisone/azathioprine group required significantly less prednisone than the prednisone-only group for myositis control and this group also had significant improvement in functional disability. 42 A major limitation of these data is that they did not assess for the presence of ILD or ILD response to therapy.
Patients receiving azathioprine should have their complete blood count and renal/liver function monitored every 1 to 3 months. 33 Adverse reactions to azathioprine include nausea, pancreatitis, hepatitis, and cytopenias. Rarely, an acute febrile hypersensitivity reaction can occur.
Mycophenolate Mofetil
Mycophenolate mofetil inhibits proliferating lymphocytes by altering purine synthesis. It is used in posttransplant antirejection regimens and is also frequently used in the treatment of CTD. Swigris and colleagues demonstrated its safety and efficacy in a heterogeneous group of patients with CTD-ILD in 2006. This case series assessed 28 patients treated with MMF for nearly 36 patient-years. 43 All but 2 patients tolerated the medication and its use resulted in a significantly lower dose of corticosteroids. A 2013 study by Fischer et al 44 demonstrated a similar tolerability of mycophenolate mofetil in 125 patients with CTD-ILD. In this study, mycophenolate mofetil treatment was associated with a stable or improved lung function over several years of follow-up. A subset of patients with IIM-ILD showed an improved lung function with mycophenolate mofetil.
Common adverse effects include nausea, diarrhea/colitis, hypertension, hyperglycemia, and cytopenias, among many more. Persistent or severe diarrhea warrants further evaluation, as it may be a sign of serious colitis. Enteric-coated mycophenolic acid is an alternative to mycophenolate mofetil, as it has been demonstrated to have fewer gastrointestinal side effects with a similar medication efficacy. 45 Providers should monitor complete blood counts every 1 to 3 months and consider monitoring drug clearance if signs of intolerance occur. 33 
Calcineurin Inhibitors: Tacrolimus and Cyclosporine
The calcineurin inhibitors tacrolimus and cyclosporine exert their anti-immune effects by the inhibition of T cells. Tacrolimus has both a greater potency and an improved safety profile when compared with cyclosporine, 46 and so may be the preferred calcineurin inhibitor in antisynthetase syndrome-ILD. To the extent that IIMs may be T-cell driven in their pathogenesis, these drugs are the logical choice as an adjunctive therapeutic agent.
A 2013 study of 18 patients with anti-Jo-1 antibodies (17 with ILD) who received cyclosporine after failing prednisone revealed that these patients had a statistically significant improvement in the forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO), without any lifethreatening complications at 1 year of follow-up. 47 Four patients stopped cyclosporine and experienced a relapse in ILD. Retreatment with cyclosporine resulted in an improvement in 2 patients.
The first successful use of tacrolimus was reported in 1999 by Oddis et al 48 in 8 patients with PM-ILD. Six of these patients had anti-Jo-1, and 2 had anti-SRP autoantibodies. Since then, numerous case reports and studies have suggested the efficacy of tacrolimus in patients with CTD and IIMrelated ILD, 49 even as an add-on therapy in combination with corticosteroids and an additional immunosuppressive agent. 50 A 2005 case series specifically studied the efficacy of tacrolimus in 15 patients with antisynthetase syndrome-ILD. Most of these patients had Jo-1 autoantibodies, and experienced an improvement in the lung function and muscle symptoms as well as a significant reduction in the corticosteroid dose with tacrolimus administration. 51 Providers should closely monitor calcineurin inhibitor serum trough levels, particularly with dosage changes, worsening myositis, or ILD, or with fluctuating renal clearance. It is our practice to initiate tacrolimus at 1 mg twice daily, and increase by 1 to 2 mg weekly until the 12-hour target trough levels reach 5 to 8 ng/mL. 50 Final doses are typically 1 to 5 mg, twice daily. Providers should closely follow the blood pressure, the renal function, electrolytes, lipids, and the complete blood count. 33 Adverse events in patients treated with tacrolimus include renal dysfunction, hyperkalemia, hyperglycemia, hypertension, tremor, and headache. If used as an add-on therapy in addition to another immunosuppressive agent, we advocate that tacrolimus should be the first agent to stop after prednisone once a patient has entered a clinical remission, given the risk of renal dysfunction with the long-term use of tacrolimus.
Rituximab
Rituximab is a monoclonal antibody that targets the CD20 surface antigen on B lymphocytes. Oddis et al 52 performed the largest randomized placebo-controlled trial of rituximab treatment for refractory adult and juvenile DM and adult PM in 2012. In this delayed-start study, 195 patients received rituximab plus nonstandardized immunosuppression either at week 1 or at week 8 with a total follow-up of 44 weeks. There was no difference in the time to myositis disease control between the groups, although 83% of the patients achieved the predefined clinical response by the end of the study. This study did not look at the presence of ILD or its response to this therapy.
Two small case series have suggested the efficacy in patients with ILD due to either CTD or antisynthetase syndrome. A 2009 case series described 11 patients with antisynthetase syndrome-ILD and a declining lung function who were treated with rituximab. 53 At short-term follow-up (approximately 7 mo), 6 of 11 patients had an improvement of over 10% in the FVC. One patient died of P. jiroveci pneumonia, a complication of chronic immunosuppression.
In 2012, rituximab was proposed as the "rescue therapy" in a case series of 8 patients with severe ILD due to CTD. 54 Four of these patients had an anti-Jo-1 antibody with HRCT, suggesting fibrotic NSIP. All of the patients included had a decline in lung function before rituximab initiation, and the follow-up 9 to 12 months later showed an improvement in pulmonary symptoms and/or lung function. A 2014 follow-up study by the same authors on 50 patients with ILD (5% with IIM) treated with rituximab again suggested efficacy. 55 Common side effects of rituximab include headache, nausea and vomiting, diarrhea, and infection. 52 Other serious adverse events include cytopenias and fatal infusion reactions. Providers should ensure that patients do not have viral hepatitis before choosing rituximab, and should monitor complete blood counts before every rituximab infusion. 33 
Cyclophosphamide
Cyclophosphamide is an antiproliferative cytotoxic agent that alkylates DNA. Given the serious nature of many of the potential adverse effects associated with its use, it is typically reserved for the treatment of severe IIM-ILD, particularly ARDS. Its efficacy in treating IIM with and without ILD has been demonstrated in several case series. A 2015 systematic review analyzed the findings of 12 studies performed between 1975 and 2014, in which 178 patients with an IIM and 141 patients with IIM-ILD were treated with cyclophosphamide. 56 With the caveat that the dosages of cyclophosphamide varied as did the coadministered immunosuppressants, approximately 71% of the patients demonstrated improvement in the vital capacity or the FVC and 69% had an improved DLCO. The most common side effects were nausea and vomiting. Several patients had evidence of opportunistic infections. Two of the most feared complications of cyclophosphamide, malignancy and hemorrhagic cystitis, were not observed.
A 2013 review of 42 patients with PM/DM-ILD compared outcomes in patients treated with cyclophosphamide, azathioprine, or mycophenolate mofetil. 57 No significant difference in the lung function was demonstrated, although 6 patients were switched to another agent from cyclophosphamide after 6 months in an attempt to avoid its toxic side effects.
Concerns over the cytotoxic effects of cyclophosphamide often limit its administration to severe and refractory antisynthetase syndrome-ILD. The use of cyclophosphamide has been linked to many different malignancies. It has also been associated with sterility, hemorrhagic cystitis, congestive heart failure, cytopenias, and opportunistic infections. Cyclophosphamide should be prescribed only by providers familiar with its adverse effects and need for frequent monitoring. Patients should have complete blood counts, renal function, and urinalysis before every administration of cyclophosphamide (usually every 1 to 2 wk). 33 
Other Therapies
Intravenous immunoglobulin (IVIG), a blood product containing the pooled immunoglobulin G antibodies from donors, is used in the treatment of many immune deficiency and autoimmune disorders, although its exact mechanism of action is unknown. In a randomized, placebo-controlled trial of IVIG treatment in 15 patients with DM, patients randomized to receive IVIG had a significant improvement in the muscle strength and symptoms. 58 A recent case report suggested that IVIG may also be effective in ILD related to IIM. 59 It is typically used as an adjunctive therapy.
Finally, despite methotrexate's demonstrated efficacy in IIM, methotrexate is typically avoided in patients with ILD due to its link to drug-induced pneumonitis. 60 Methotrexate has demonstrated utility in active myositis and is considered as the first-line therapy in IIM patients without ILD; therefore, methotrexate may be required in refractory muscle disease. Its use in patients with ILD necessitates careful pulmonary monitoring.
COMORBIDITIES AND SURVIVAL

Pulmonary Hypertension
Patients with ILD are at an additional risk for developing pulmonary hypertension (PH), as compared with IIM patients without ILD, which causes increased morbidity and mortality. In a 2013 study of 203 antisynthetase syndrome patients with ILD and/or myositis/arthritis symptoms, 23.2% had a transthoracic echocardiogram suggestive of PH. 13 Of the 47 patients suspected of PH, 45% had a right heart catheterization performed after the echocardiogram, which confirmed PH in 7.9% of the total study population. All 16 patients with confirmed PH had ILD. Survival in patients with PH and ILD was significantly lower than in patients with ILD who did not have PH.
Malignancy
DM has long been associated with an increased risk of malignancy; however, there is little evidence to guide the evaluation for malignancy in patients with antisynthetase syndrome. The first case report of cancer-associated antisynthetase syndrome was in 2008, in a 59-year-old patient with colon adenocarcinoma. 61 Several case reports and series have followed, with widely varying prevalence rates, up to approximately 14%. 19, 62, 63 In a larger retrospective analysis of 233 patients with antisynthetase syndrome, the frequency of cancer was only 1.7% within 3 years from antisynthetase syndrome diagnosis, which the authors assert was not much different than the general population in France. 64 These studies suggest that care providers of these patients should follow age-appropriate cancer screening, but there is no evidence to guide additional or non-guideline-based evaluation. Interestingly, the treatment of the underlying malignancy has been demonstrated in case reports to improve myositis and ILD, 65 further suggesting that IIM can be a paraneoplastic syndrome.
Survival
Several studies suggest that patients with anti-PL7/PL12 autoantibodies have aggressive ILD and decreased survival as compared with those with anti-Jo-1 autoantibodies. In addition, patients with other antisynthetase antibodies may not be diagnosed appropriately, which may slow the institution of therapy. One retrospective review found a 0.6-year median delay to diagnosis in patients with a non-Jo-1 antisynthetase antibody compared with patients with a Jo-1 antibody. 66 In an analysis of patients with antisynthetase syndrome, decreased survival was seen in patients without muscle weakness and with severe dyspnea. 64 Patients with anti-PL7 or anti-PL12 often have severe and difficult-to-treat ILD, frequently without myositis, 67 suggesting that the pulmonary manifestations of antisynthetase syndrome are responsible for the difference in mortality. These findings were reproduced in a 2014 metaanalysis of 27 studies on antisynthetase syndrome, in which the authors found that arthralgia and ILD predominate in antisynthetase syndrome as compared with the other IIMs, and patients with Jo-1 have more myositis and a better prognosis compared with PL7 and PL12. 68 In a 2015 survival analysis of 45 patients with antisynthetase syndrome-ILD, 14% of the patients had died at 5 years. 69 Survivors more frequently had Jo-1 positivity and arthritis. Patients who died had a significantly lower baseline FVC, and most of them could not perform DLCO due to the severity of the disease. A 2013 retrospective evaluation of 202 patients, with an antisynthetase antibody from the University of Pittsburgh CTD Registry during a 24-year time period, found a 5-year cumulative survival of 90% for Jo-1 patients and 75% for non-Jo-1 patients. 66 The 10-year survival was 70% for Jo-1 patients and 49% for non-Jo-1 patients. The most common causes of death were pulmonary fibrosis and PH. Of this cohort, 6% underwent lung transplantation. As patients with ILD due to antisynthetase syndrome often have severe and aggressive ILD requiring multimodality therapy, physicians should consider early referral to centers capable of lung transplantation when disease progresses or fails to respond adequately to treatment.
CONCLUSIONS
Antisynthetase syndrome, characterized by the presence of an anti-tRNA synthetase antibody along with a distinct phenotype that includes a high burden of ILD, is an increasingly recognized clinical entity within the IIMs. ILD associated with antisynthetase syndrome is often more severe and rapidly progressive when compared with other IIMs, which contributes to the increased morbidity and mortality seen in antisynthetase syndrome (Table 5 ).
Diagnosis is undertaken by a comprehensive history and physical examination focused on CTD signs and symptoms that include Raynaud's phenomenon, mechanic's hands, unexplained fever, myositis, and nonerosive arthritis. HRCT imaging along with pulmonary function testing is crucial in screening for and characterizing the extent of pulmonary involvement. Muscle and lung biopsies are infrequently required for diagnosis, but can aid in understanding the severity of the disease and the likelihood of response to therapy.
Immunosuppressive agents, such as azathioprine, mycophenolate mofetil, and/or tacrolimus, are usually required in addition to corticosteroids for the management of the myositis and pulmonary manifestations of antisynthetase syndrome. No study has demonstrated the superiority of a particular agent, and so the choice of therapy is guided by the practitioner's comfort and a careful assessment of potential risks of the therapy in an individual patient. Our practice is to initiate prednisone and azathioprine or mycophenolate mofetil in patients with antisynthetase syndrome-related ILD, with the addition of tacrolimus for rapid disease control in more severe ILD. 50 In the setting of antisynthetase syndrome, we use rituximab for patients with severe progressive and/or refractory ILD and have used cyclophosphamide in ARDS.
In addition to monitoring ILD and myositis, providers should carefully attend to other comorbidities associated with antisynthetase syndrome, including PH, and screen for malignancy. Survival is decreased in patients with antisynthetase syndrome-ILD as compared with patients with an IIM in general. Survival also seems to vary in antisynthetase syndrome depending on the autoantibody present, with Jo-1 having the best prognosis. Referral to tertiary-care centers capable of lung transplantation should be considered in patients with severe and/or rapidly progressive ILD.
Evidence guiding management decisions is limited, and is primarily based on case reports and series. Prospective studies are urgently needed to guide treatment choices and determine as to which immunosuppressive agents offer control of disease and an improved survival. It is also imperative that studies examine the rate of relapse when these therapies are withdrawn, so as to guide the length of therapy. Suspect if unexplained acute respiratory distress syndrome, idiopathic interstitial lung disease (particularly NSIP and/or OP), Raynaud's phenomenon, fever, and/or mechanic's hands Anti-Jo-1, anti-PL 7, and anti-PL 12 are the most frequently noted antisynthetase antibodies; ANA and anti-Ro/SSA may suggest myositis-related ILD Patients have more severe and aggressive ILD as compared with the other idiopathic inflammatory myopathies Often requires multimodality immunosuppression First-line therapy is prednisone AND mycophenolate mofetil or azathioprine; consider tacrolimus as add-on therapy Monitor pulmonary function tests every 2-3 mo unless in remission If ILD progresses despite therapy, refer for lung-transplant evaluation
